In order to concentrate management resources into pharmaceutical businesses, Takeda divested its animal health business, bulk vitamin business, urethane chemicals business, food business, agricultural business, and life-environment business as a part of the 2001-2005 Mid-Term Growth Strategy.
Takeda Pharma GmbH and its two wholly owned subsidiaries, Takeda Pharma Ges.m.b.H in Austria and Takeda Pharma AG in Switzerland, became wholly-owned subsidiaries of Takeda Europe Holdings B.V. The same year, Takeda Pharma Ireland Limited was established to strengthen Takeda's global manufacturing network. This bulk pharmaceutical plant was later integrated into Takeda Ireland Limited in 2009.
U.S. bio-venture Syrrx, Inc. was integrated into Takeda's global R&D network and currently operates under the name Takeda California, Inc.
Syrrx possessed the world's best high-throughput X-ray crystallography technology for analyzing proteins at the time, and the integration of Syrrx represented the first expansion of Takeda's drug discovery program outside of Japan.
Rozerem (generic name: ramelteon) has a different mechanism of action to conventional insomnia treatments. It acts on melatonin receptors to induce a state close to physiologically natural sleep.
Takeda Pharmaceuticals Europe Limited led operations in Europe and accelerated strategies across Europe with a mid- to long term perspective.
The completion of new home offices in the United States for both Takeda Pharmaceuticals North America and the Takeda Global R&D Center was a great achievement in order to continue to strengthen our presence in North America and fortify our operations in the U.S.
Takeda has published an integrated annual report incorporating non-financial information about our initiatives on human rights, the environment, and communities, in addition to financial information.
To ensure our disclosure to stakeholders is as full as possible, we have also compiled the CSR Data Book. Available only in PDF and e-book format out of consideration for the environment, the CSR Data Book contains further details about the CSR information found in the Annual Report in a re-edited form: CSR Data Book
Through the integration of Paradigm Therapeutics and its subsidiary in Singapore, Takeda further enhanced our multi-IND engines. Paradigm Therapeutics Ltd. was a bio-venture established by researchers of the University of Cambridge in 1999. Paradigm has already developed a promising pipeline of novel drug discovery targets and compounds that overlap with Takeda's core therapeutic areas. Paradigm Therapeutics Ltd. currently goes under the names of Takeda Cambridge Limited (TCB) and Takeda Singapore Pte. Limited (TSP).
Through this integration, Takeda reinforced its marketing and development functions in the U.S., as well as further promoted efficiencies throughout its business operations. In agreement with Abbott Laboratories, TAP became a wholly-owned subsidiary of Takeda and was merged into Takeda Pharmaceuticals North America, Inc. (TPNA), and subsequently TAP's development function was integrated into Takeda Global Research & Development Center Inc. (TGRD).
Millennium is one of the world's leading biopharmaceutical companies, possessing a strong R&D pipeline in the oncology area. The company is a pioneer in the field of protein homeostasis research. By leveraging the complementary strengths of Millennium and Takeda, we will benefit from considerable synergies, both from Millennium's excellence in knowledge, technology and experience in the oncology area.
Takeda aPharmaceuticals (Asia Pacific) Pte. Limited (TPAP), based in Singapore, is responsible for the strategic and commercial operations in Australia, Thailand, Philippines, Indonesia, India, Malaysia and Singapore. Fully integrated into the global development organization, Takeda Clinical Research Singapore (currently operating under the name TDC Asia) serves as a regional hub for non-oncology clinical development. TDC Asia seeks to bring innovative products to people through a pipeline that includes compounds in a variety of therapeutic areas.
Dexilant (generic name: dexlansoprazole) is the first proton pump inhibitor specifically designed for the release of medicine in two stages over time. It has a powerful and sustained suppressant effect on gastric acid secretion.
Discovered by Teijin Pharma Limited, Uloric (generic name: febuxostat) is a treatment for hyperuricemia in patients with gout. It lowers the level of uric acid in the blood of hyperuricemic patients with gout by blocking the enzyme that is responsible for the synthesis of uric acid.
Takeda supports the United Nations Global Compact's 10 principles relating to "Human Rights," "Labor," "Environment" and "Anti-Corruption," and has incorporated them into every aspect of its business activities. Moreover, Takeda enhanced its CSR activities by establishing a dedicated CSR organization in 2009.
Takeda has formed long-term, ongoing partnerships with international NGOs and other groups to support their efforts to improve access to healthcare for people in developing countries. The "Takeda Initiative" is a 10-year grant program running from 2010 to 2019 to support the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) by helping it develop the capacity of healthcare providers in three countries in Africa. For example in Nigeria, more than 11,000 teachers received training in AIDS education in 2012 through programs which were partly supported by the Takeda Initiative, and they went on to teach more than 1.2 million students about AIDS. As a result of these kinds of activities, the HIV infection rates among young people in Nigeria have been falling.
Takeda instituted the Takeda Global Code of Conduct as a baseline standard of compliance commonly applicable to Takeda Group companies to help promote an integrated approach to compliance issues across Takeda operations worldwide.
Azilva (generic name: azilsartan) is an angiotensin II receptor blocker (ARB).
The Shonan Research Center is located in the cities of Fujisawa and Kamakura in Kanagawa Prefecture. The new facility integrates the Osaka and Tsukuba research centers as the nucleus of Takeda's global research network to accelerate innovation in drug discovery. Around 1,200 researchers at the center will work through the various stages of the R&D process, from the initial search for drug discovery targets, the selection of candidate compounds to the nonclinical research until launch.
The integration of the Swiss pharmaceutical company Nycomed was completed in September 2011. Nycomed is a company with a strong presence in Europe and developing countries. Due to the integration, Takeda has expanded its market to over 70 countries and has been able to enhance its sales structure and expertise in order to deliver pharmaceutical products to more patients and medical personnel around the world.
Since January 2011, as a member of the United Nations Global Compact LEAD Program, Takeda has helped to lead corporate efforts worldwide to implement and disseminate the 10 principles of the Compact relating to areas such as human rights, labor standards, the environment, and anti-corruption.
Takeda is supporting the recovery of areas affected by the Great East Japan Earthquake by donating some of the profits from Alinamin. The Group is also promoting a variety of other long-term, ongoing support programs.
Vaccines have had a tremendous impact on global public health in recent years. Takeda made the decision to globalize its vaccine business, which has been active in Japan for over 60 years.
The Vaccine Business Division is taking a number of steps to strengthen Takeda's existing vaccine business in Japan as well as steps to develop pediatric vaccines in-house and enhance the R&D pipeline by in-licensing novel vaccine candidates and novel vaccine development platforms.
・URL Pharma, Inc.: Added the leading product Colcrys (colchicine) to our portfolio for the treatment of gout flares.
・Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda.: Greatly expanded our presence and product portfolio in Brazil.
・LigoCyte Pharmaceuticals, Inc.: Strengthened our vaccine business. (Currently Takeda Vaccines (Montana), Inc.)
・Envoy Therapeutics, Inc.: Strengthened our drug discovery platform to enable the identification of novel targets.
Takeda established a global policy on Environment, Health, and Safety, and promoted comprehensive initiatives.
EHS-related activities span various issues of concern to the global community such as the use of water resources and conservation of biodiversity. Specific future plans include assessment and analysis of the environmental impact of Group products over their life cycle and a detailed approach to environmental accounting through utilization of LIME and other means.
This treatment for relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma was in-licensed from Seattle Genetics, Inc and launched by Takeda in the EU in 2012 and Japan in 2014. For patients suffering from these rare conditions, this prescription drug will provide another treatment option.
Lotriga (generic name: Omega-3-Acid Ethyl Esters 90) is a highly concentrated omega-3-derived prescription drug that was in-licensed from Pronova BioPharma ASA. It is the first prescription medicine in Japan that contains both EPA and DHA.
Nesina (generic name: alogliptin benzoate) was originally discovered by Takeda California, Inc., and is a type 2 diabetes treatment that lowers blood glucose levels by inhibiting an enzyme (DPP-4) that breaks down glucagon-like peptide-1 (GLP-1), a hormone that stimulates secretion of insulin.
The Women's Empowerment Principles (WEPs) are a set of principles for businesses offering guidance on how to empower women in the workplace. These principles are the result of a collaboration between the United Nations Entity for Gender Equality and the Empowerment of Women (UN Women) and the United Nations Global Compact. Takeda signed the CEO Statement of Support for the WEPs in December 2013 and plans to follow the seven principles to enhance its initiatives for promoting the active participation of women in corporate activities.
Through the integration of Inviragen, Inc. (based in Colorado, U.S.), we acquired innovative pipeline candidates and cutting-edge vaccine technologies for both live-virus and inactivated virus vaccines that greatly enhanced our presence in the global vaccine market.
This treatment for Major Depressive Disorder was in-licensed from Lundbeck of Denmark. Trintellix has a different mechanism from existing treatments, and is therefore expected to contribute to the treatment of depression for many patients.
* The product name was changed from Brintellix to Trintellix(2016)
Entyvio is a product that offers a treatment option to patients with inflammatory bowel disease who have failed to respond to treatment with existing products. Entyvio was launched by Takeda in both the EU and the US in June 2014.
NINLARO was approved in the U.S. in 2015 as the first oral proteasome inhibitor and is the result of decades of Nobel-prize winning science and research in multiple myeloma.
Date of Preparation: April 2018